Kristen Hallam on Muck Rack

Kristen Hallam

As seen in: Bloomberg News, Bloomberg Businessweek, The Boston Globe, New Zealand Herald, Buffalo News, Accounting Today, Salt Lake Tribune, Livemint and 69 more
Covers:  science, health policy, biotechnology, mergers & acquisitions, health, pharmaceutics
Doesn't Cover: clinical trial initiation, new product launches

@BloombergNews health editor in London. @NorthwesternU alum, @AHCJ member. Email: RTs & links not endorsements.

Bristol-Myers Asked to Seek Special Coverage for Opdivo in U.K. — Bristol-Myers Squibb Co.'s Opdivo lung-cancer treatment isn't cost-effective for all patients, and the company should seek to make it accessible to some through a special U.K. government program, the country's health-cost regulator said.

AstraZeneca’s Brilinta Fails to Beat Older Medicine in Trial — AstraZeneca Plc's heart medicine Brilinta didn't beat a generic blood-thinner in patients with peripheral artery disease, the latest blow to the drugmaker's ambitions for the treatment after it failed a test in March. Brilinta was pitted against clopidogrel in a trial of almost 14,000 people in 28 countries, the largest test of its kind in patients with symptoms of the disease.

ConvaTec to Raise $1.8 Billion in London Initial Offering — ConvaTec Ltd., a medical technology company whose shareholders include Nordic Capital and Avista Capital Partners, said it plans to raise $1.8 billion in an initial public offering in London. The shares would trade on the main market of the London Stock Exchange starting in late October or early November, the company said Monday in a statement.

Boston Scientific to Buy Endoscopy Company in $210M Deal — Boston Scientific Corp. agreed to buy EndoChoice Holdings Inc. for about $210 million to expand its endoscopy business. The $8-a-share purchase price is almost double EndoChoice's closing price of $4.22 as of Monday. The deal is expected to complete in the fourth quarter, Marlborough, Massachusetts-based Boston Scientific said Tuesday in a statement.

AstraZeneca Withdraws EU Application for Ovarian-Cancer Therapy — AstraZeneca Plc said it is withdrawing an application for European approval for an ovarian-cancer medicine following disagreement with regulatory authorities. The decision won't affect the ongoing development of the treatment, called cediranib, the Cambridge, England-based company said today in an e-mailed statement.

Big Pharma’s Latest Breakthrough: Choosing Its First Female CEO

Big Pharma’s Latest Breakthrough: Choosing Its First Female CEO — GlaxoSmithKline Plc's new chief executive looks a lot like other bosses at large pharmaceutical companies: a graduate of Oxford, white, with worldwide experience managing thousands of employees. There is, though, one big difference: She's not a man.

Crops Would Eclipse Drugs at Bayer After Monsanto Deal: Chart — The balance seems to be shifting at Bayer AG. By buying Monsanto Co., the German company would see its crop-science unit surpass pharmaceuticals in sales. The health-care business generated about 44 percent of sales last year, more than any other Bayer division.

Horizon Pharma Buys Rare-Disease Company Raptor for $800 Million

Departing Pharma CEOs Leave Waning Sales for Successors to Solve — Another pharmaceutical chief executive is riding off into the sunset, the latest departure in an industry struggling to invent new medicines amid unprecedented pricing pressure. Novo Nordisk A/S's Lars Rebien Soerensen, chosen by Harvard Business Review as the world's best-performing CEO last year, is retiring from the world's biggest maker of insulin, the company said Thursday.
More Articles →
Oct 21, 2016

RT @markets: #5Things -Tobacco offer -Euro at March lows -May's 100 days -Markets mixed -Trump will accept 'clear' result…

Oct 21, 2016

In the "things I never thought about before I became a parent" category of news -- 

Oct 20, 2016

RT @scotthensley: Theranos approach to test quality: “They were just going through the motions,” reports @cdweaver re: patient harm.

Oct 20, 2016

The newest way to fund fertility treatment is to ask strangers for money:  via @business

Oct 20, 2016

Monsanto talked to three other companies before Bayer deal  via @markets

Oct 20, 2016

RT @jar_ko: @kristen_hallam @BloombergTV @business depends on how you define 'mega' with ca. CHF9bn in cash sitting around

Oct 20, 2016

RT @jar_ko: Actelion Using Combination Strategy to Attack Multiple Sclerosis  via @business

Are You a Journalist?

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Create a Portfolio